BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21716127)

  • 1. Effect of beclomethasone nasal spray on intraocular pressure in ocular hypertension or controlled glaucoma.
    Yuen D; Buys YM; Jin YP; Alasbali T; Trope GE
    J Glaucoma; 2013 Feb; 22(2):84-7. PubMed ID: 21716127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Controlled Trial to Determine the Effect of Inhaled Corticosteroid on Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension: The ICOUGH Study.
    Moss EB; Buys YM; Low SA; Yuen D; Jin YP; Chapman KR; Trope GE
    J Glaucoma; 2017 Feb; 26(2):182-186. PubMed ID: 27096722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
    Sonty S; Mundorf TK; Stewart JA; Stewart WC
    Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
    Hatanaka M; Reis A; Sano ME; Susanna R
    J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
    Am J Ophthalmol; 2013 Oct; 156(4):731-6. PubMed ID: 23831221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
    Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy.
    Goldberg I; Crowston JG; Jasek MC; Stewart JA; Stewart WC;
    J Glaucoma; 2012 Jan; 21(1):55-9. PubMed ID: 21048504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial.
    Gagliano C; Ortisi E; Pulvirenti L; Reibaldi M; Scollo D; Amato R; Avitabile T; Longo A
    Invest Ophthalmol Vis Sci; 2011 Aug; 52(9):6096-100. PubMed ID: 21705689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
    J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroids versus NSAIDs on intraocular pressure and the hypertensive phase after Ahmed glaucoma valve surgery.
    Yuen D; Buys Y; Jin YP; Alasbali T; Smith M; Trope GE
    J Glaucoma; 2011 Sep; 20(7):439-44. PubMed ID: 20852441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monocular trial of intraocular pressure-lowering medication: a prospective study.
    King AJ; Uppal S; Rotchford AP; Lakshumanan A; Abedin A; Henry E
    Ophthalmology; 2011 Nov; 118(11):2190-5. PubMed ID: 21724262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension.
    Williams RD; Novack GD; van Haarlem T; Kopczynski C;
    Am J Ophthalmol; 2011 Nov; 152(5):834-41.e1. PubMed ID: 21794845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of topical 0.05% flunarizine in patients with open-angle glaucoma or ocular hypertension-a pilot study.
    Mansouri K; Silva SE; Shaarawy T
    J Glaucoma; 2011 Oct; 20(8):519-22. PubMed ID: 21048514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
    Cantor LB; WuDunn D; Cortes A; Hoop J; Knotts S
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Prospective, randomized, investigator-masked evaluation of the monocular trial in ocular hypertension or open-angle glaucoma.
    Realini TD
    Ophthalmology; 2009 Jul; 116(7):1237-42. PubMed ID: 19576495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of IOP reduction with travoprost BAK-free solution.
    Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
    J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.